Stock S1RP34 SAREPTA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Sarepta Therapeutics, Inc. Sao Paulo

Equities

S1RP34

BRS1RPBDR005

Market Closed - Sao Paulo
Other stock markets
 02:17:18 2024-07-08 pm EDT 		5-day change 1st Jan Change
41.49 BRL -0.07% Intraday chart for Sarepta Therapeutics, Inc. -6.22% +80.71%
Jun. 26 Monetary policy is getting even more confusing Our Logo
Jun. 26 Citigroup Downgrades Sarepta Therapeutics to Neutral From Buy, Raises Price Target to $176 From $172 MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
Monetary policy is getting even more confusing
Our Logo
Citigroup Downgrades Sarepta Therapeutics to Neutral From Buy, Raises Price Target to $176 From $172
MT
Citigroup Upgrades Sarepta Therapeutics to Neutral From Buy, Adjusts PT to $176 From $172
MT
ANALYST RECOMMENDATIONS : Accenture, Chipotle, Rivian, Walmart, Humana...
Our Logo
Morgan Stanley Adjusts Sarepta Therapeutics' Price Target to $200 From $165, Keeps Overweight Rating
MT
Evercore ISI Raises Price Target on Sarepta Therapeutics to $185 From $139, Maintains In Line Rating
MT
Key week for monetary policy
Our Logo
BMO Capital Raises Price Target on Sarepta Therapeutics to $200 From $170, Maintains Outperform Rating
MT
ANALYST RECOMMENDATIONS : Accenture, Walgreens Boots Alliance, Ge Vernova, Pepsico, Britvic...
Our Logo
Sarepta Therapeutics, Ryan Specialty rise; Autodesk, Trump Media fall, Friday, 6/21/2024
AQ
Health Care Stocks Boosted By Duchenne MS Drug -- Health Care Roundup
DJ
Sector Update: Health Care Stocks Gain in Late Afternoon
MT
S&P, Nasdaq edge down as Nvidia declines for second day
RE
Top Midday Gainers
MT
Sector Update: Health Care Stocks Edge Up in Afternoon Trading
MT
Sarepta Therapeutics' Gets Label Expansion for Elevidys in 'Best-case Scenario,' BofA Securities Says
MT
S&P 500, Nasdaq lower as semiconductor shares weigh
RE
Barclays Adjusts Price Target on Sarepta Therapeutics to $226 From $185, Maintains Overweight Rating
MT
Sarepta surges as investors cheer expanded use of gene therapy
RE
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SRPT Stock
  4. S1RP34 Stock
  5. News Sarepta Therapeutics, Inc.